BioAge Labs, Inc. (BIOA)

BioAge Labs Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Revenue	9	-	-	-
Gross Profit	9	-	-	-
Selling, General & Admin	27.81	19.16	14.51	9.45
Research & Development	73.97	59.04	33.89	30.52
Total Operating Expenses	101.78	78.19	48.4	39.97
Operating Income	-92.78	-78.19	-48.4	-39.97
Interest Income	13.09	9.63	2.43	0.47
Interest Expense	-0.7	-2.37	-7.79	-0.24
Other Non-Operating Income (Expense)	-0.21	-0.18	-10.09	0.02
Total Non-Operating Income (Expense)	12.18	7.09	-15.45	0.25
Pretax Income	-80.61	-71.11	-63.85	-39.72
Net Income	-80.61	-71.11	-63.85	-39.72
Net Income to Common	-80.61	-71.11	-63.85	-39.72
Shares Outstanding (Basic)	36	11	2	2
Shares Outstanding (Diluted)	36	11	2	2
Shares Change (YoY)	234.99%	541.23%	0.06%	-
EPS (Basic)	-2.24	-6.63	-38.17	23.76
EPS (Diluted)	-2.24	-6.63	-38.17	23.76
Free Cash Flow	-82.35	-51.89	-37.53	-36.28
Free Cash Flow Per Share	-2.29	-4.84	-22.43	-21.70
Gross Margin	100.00%	-	-	-
Operating Margin	-1031.46%	-	-	-
Profit Margin	-896.11%	-	-	-
FCF Margin	-915.46%	-	-	-
EBITDA	-92.57	-78.03	-48.24	-39.84
EBITDA Margin	-1029.09%	-	-	-
EBIT	-92.78	-78.19	-48.4	-39.97
EBIT Margin	-1031.46%	-	-	-

Updated Mar 24, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q